Abstract

Abhishek*, Chandanam Sreedhar, Harsha K. Tripathy, T. Srinivasa Rao, Manju S. V. and Gokulraj S

ABSTRACT

Diabetes mellitus is increasingly prevalent due to modern lifestyle factors such as dietary habits, medication use, traditions, and lifestyle changes. Effective management of type 2 diabetes often requires the use of combination drug therapies, as single drugs may not provide sufficient control. Metformin HCL, a biguanide antihyperglycemic agent, and dapagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) inhibitor, represent a promising combination for the treatment of type 2 diabetes. This study presents a comprehensive analysis of metformin HCL and dapagliflozin, focusing on their mechanisms of action, drug profiles, and the efficacy of their combination therapy. Various analytical techniques, including Reverse Phase High-Performance Liquid Chromatography (RP-HPLC), High-Performance Liquid Chromatography (HPLC), Ultraviolet (UV) spectroscopy, and Liquid Chromatography-Mass Spectrometry (LC-MS), were employed to analyse the drugs in both bulk and pharmaceutical dosage forms. The findings highlight the enhanced efficacy of double combination therapy with metformin HCL and dapagliflozin in managing type 2 diabetes mellitus, and provide detailed insights into their analytical profiles.